LLY vs TGTX: fair value comparison
Eli Lilly and Company and TG Therapeutics, Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, TGTX currently sits closer to the top of our discount ranking.
| LLY | TGTX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $1,149.36 | $46.17 |
| 12-month range | $862.86–$1,160.00 | $29.18–$53.52 |
| Sector rank | #11 of 113 Healthcare | #2 of 113 Healthcare |
| Quality grade | D | D |
| Leverage | High | — |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: LLY fair value analysis · TGTX fair value analysis